[September 13, 2017]

Global Sexual Dysfunction Drugs Market 2017-2021: Key Vendors are AbbVie, Bayer, Eli Lilly & Pfizer - Research and Markets

The "Global Sexual Dysfunction Drugs Market 2017-2021" report has been added to Research and Markets' offering.

The report forecasts the global sexual dysfunction drugs market to grow at a CAGR of 2.79% during the period 2017-2021.

The report, Global Sexual Dysfunction Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is the increased focus on generic drugs. The global sexual dysfunction drugs market is currently witnessing an increasing focus of vendors toward the launch of generic drugs in the market. The patent expiration of many ED drugs has led to the entry of generics in the market. The cost-effective nature and the abundant availability of these drugs have led to the increase in the adoption rate of these drugs among physicians and end-users, thus adding to the marketrevenue.

According to the report, one of the major drivers for this market is the rising prevalence of sexual dysfunctions. The global sexual dysfunction drugs market is currently witnessing an increasing prevalence rate of sexual dysfunction disorders in men and women. As per the NIH, the incidence rate of ED is 25-30 cases per thousand people per year globally, and this rate is directly proportional to age. A similar pattern is observed with women's sexual dysfunctions.

Key vendors

• AbbVie
• Bayer
• Eli Lilly
• Pfizer

Other prominent vendors

• Apricus Biosciences
• Emotional Brain
• GlaxoSmithKline
• Ivix LLX
• Leadiant Biosciences
• Merck
• NexMed
• Palatin Technologies and PRA Health Sciences
• S1 Biopharma
• Takeda
• Teva Pharmaceutical Industries
• Trimel Biopharma SRL
• Vietstar Biomedical Research

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Disease Overview

Part 06: Market Landscape

Part 07: Pipeline

Part 08: Market Segmentation By Therapy

Part 09: Geographical Segmentation

Part 10: Decision Framework

Part 11: Drivers And Challenges

Part 12: Market Trends

Part 13: Vendor Landscape

Part 14: Key Vendor Analysis

Part 15: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/pr3bs8/global_sexual

View source version on businesswire.com: http://www.businesswire.com/news/home/20170913005662/en/

[ Back To TMCnet.com's Homepage ]